Search

Your search keyword '"Tumiotto, C"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Tumiotto, C" Remove constraint Author: "Tumiotto, C"
35 results on '"Tumiotto, C"'

Search Results

1. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

2. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

5. Modulation of the functional interfaces between retroviral intasomes and the human nucleosome

6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

7. Modulation of the functional interfaces between retroviral intasomes and the human nucleosome

8. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

9. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

10. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

11. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

12. Incidence d’infection par le virus Zika (ZKV) et défaut de performance des tests Elisa chez des voyageurs français ayant visité l’Amérique latine et/ou les Caraïbes durant l’été 2016

14. Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.

15. Trends in epidemiology and risk factors of opportunistic infections in kidney transplant recipients between 2004 and 2017.

16. Mechanisms of systemic low-grade inflammation in HIV patients on long-term suppressive antiretroviral therapy: the inflammasome hypothesis.

17. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.

18. Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France.

19. Epidemiological and clinical insights from SARS-CoV-2 RT-PCR crossing threshold values, France, January to November 2020.

20. Modulation of the intrinsic chromatin binding property of HIV-1 integrase by LEDGF/p75.

21. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.

22. A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort.

23. HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus.

24. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA.

25. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

26. Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis.

27. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

28. Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles.

29. A New HIV-1 Circulating Recombinant Form (CRF98_cpx) Between CRF06_cpx and Subtype B Identified in Southwestern France.

30. Diversity of HIV-1 in Aquitaine, Southwestern France, 2012-2016.

31. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.

32. Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients.

33. Rapid Adenovirus typing method for species identification.

34. Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA.

35. High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.

Catalog

Books, media, physical & digital resources